The Levinson building?
Executive Summary
As part of the $200 mil. settlement between Genentech and the University of California-San Francisco over patents on recombinant human growth hormone, Genentech will contribute $50 mil. towards the construction of the first biological sciences research building on the new UCSF Mission Bay campus. Genentech will have the rights to name the building. The agreement provides $35 mil. in additional funding to UCSF and $30 mil. to the University of California general fund. Five researchers will share the remaining $85 mil. Genentech CEO Arthur Levinson, PhD, was a postdoctoral fellow at UCSF
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth